Jenburkt, a
120 crore pharma company has proven that small can be mighty. It has launched
Favivent its brand of Favipiravir almost at a generic price of Rs.39 a tablet
compared to the biggies with Rs.75 a tablet. Hats off to Ashish Bhuta the MD
and CEO of Jenburkt Pharmaceuticals Limited who said “Given the current scenario of grave health concerns and
economic challenges surrounding COVID-19 in India, if we as a pharmaceutical
company cannot make a significant positive difference to the society, our
company's very existence is inconsequential”. Earlier this year, the
Drug Controller General of India (DCGI) had approved the use of Favipiravir —
an antiviral drug developed in Japan and commonly used for treating influenza —
for the treatment of mild to moderate cases of COVID-19 in India.
No comments:
Post a Comment